Meningioma

Hirntumor-Informationstag 2023

Experten verschiedener Fachrichtungen und Kliniken informieren über aktuelle Erkenntnisse der Hirntumortherapie. Die Veranstaltung richtet sich bundesweit an Patienten und ihre Familien. Erfahren Sie Neuigkeiten aus Wissenschaft und Forschung.

mehr Informationen

Online-Anmeldung 

Meningiomas are tumours arising from the meninges, the membranous layers surrounding the central nervous system. These tumours are usually  benign, many of them are producing no symptoms throughout a patient's life, so that they require no treatment.

Please note that the following threads of our forum are currently only available in German language.

Different Types of Meningioma

• meningothelial meningioma (WHO grade I)
• fibroblastic meningioma (WHO grade I)
• transitional (mixed) meningioma (WHO grade I)
• psammomatous meningioma (WHO grade I)
• angiomatous meningioma (WHO grade I
• microcystic meningioma (WHO grade I)
• secretory meningioma (WHO grade I)
• lymphoplasmacyte-rich meningioma (WHO grade I)
• metaplastic meningioma (WHO grade I)
• chordoid meningioma (WHO grade II)
• clear cell meningioma (WHO grade II)
• atypical meningioma (WHO grade II)
• papillary meningioma (WHO grade II, III)
• rhabdoid meningioma (WHO grade III)
• anaplastic meningioma (WHO grade III)

Histology of Meningeoma

• slowly growing, benign meningeoma (WHO-grade I)
• atypical meningeoma, tending to relapses (WHO-grade II)
• fast growing, anaplastic meningeoma (WHO-grade III)

Epidemiology of Meningeoma

• 85% of all meningeoma are benign, 8-10% are atypical and 2-5% anaplastic
• average age between 50 and 60
• women are a little more often affected

Symptoms of Meningeoma

• depending on location and the compression which is connected to it
• signs of cerebral pressure (e.g. headache)
• neurological deficits (e.g. impaired vision, uncertain gait)
• epilepsy
• often patients don´t feel any symptoms

Diagnosing Meningeoma

• diagnosis with CT and MRI
• if necessary MR-angiography, functional MRI, MR-spectroscopy, PET
• clearly defined lesion with perifocal edema
• intensive, homogenous enhancement of contrast agent
• tends to calcification
• 9% oft he patients have more than one meningeoma
• 27% of meningeoma feature genetic modifications (monosomy 22)
• occurs more often in patients with neurofibromatosis type II and preceding radiotherapy
• possibly faster growth in pregnancy

Therapy of Meningeoma

• if possible, complete surgical removal of brain tumour
• preoperative embolisation possible  in vascular-rich tumours
• treatment of anaplastic menigeoma with additional radiotherapy
• small, asymptomatic meningeomas therapy is not always necessary

Therapy of Recurrent Meningeoma

• re-operation
• (second) irradiation
• chemotherapy, e.g. with hydroxyurea
• experimental therapy, e.g. with antiangiogenic approaches

Aftercare of Meningeoma

• check-up every 6 to 12 months
• if necessary ophthalmological, neurological and endocrinological examinations

Course of Meningeoma

• slow, extrusive growth with branches in dura mater

Prognosis of Menigeoma 

• complete surgical removal of benign meningeoma i soften equivalent to a cure
• frequency of recurrences of WHO-grade I: 7-20%
• frequency of recurrences of WHO-grade II: 30-40%
• frequency of recurrences of WHO-grade III: 50-80%

Weitere Hilfsangebote für Meningeompatienten

Aktuelles